EXEL vs. CSLLY: Which Stock Is the Better Value Option? [Yahoo! Finance]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Yahoo! Finance
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics, including the P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help determine a company's fair value. EXEL currently has a forward P/E ratio of 18.06, while CSLLY has a forward P/E of 26.41, indicating that EXEL may be undervalued compared to CSLLY. EXEL has a PEG ratio of 0.77, while CSLLY has a PEG ratio of 1.80. The PEG ratio takes into account the company's expected earnings growth rate, and a lower ratio indicates that the stock may be undervalued. Based on the analysis, EXEL is considered the better value opportunity due to its stronger estimate revision activity and more attractive valuation metrics, earning it a Value grade of B compared to CSLLY's Value grade of C. Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and CSL Limited Sponsored ADR (C
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership SummitBusiness Wire
- Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Barclays PLC from $25.00 to $29.00. They now have an "equal weight" rating on the stock.MarketBeat
- Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.MarketBeat
- Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Citigroup Inc. from $38.00 to $45.00. They now have a "buy" rating on the stock.MarketBeat
- Exelixis, Inc. (NASDAQ: EXEL) had its "equal weight" rating re-affirmed by analysts at Stephens. They now have a $29.00 price target on the stock.MarketBeat
EXEL
Earnings
- 2/11/25 - Beat
EXEL
Sec Filings
- 2/14/25 - Form 144
- 2/14/25 - Form 144
- 2/14/25 - Form 144
- EXEL's page on the SEC website